By CERBIOS-PHARMA SA
Cerbios-Pharma brings latest CDMO offerings to BIO 2022 in California
Lugano, Switzerland: – Pharmaceutical CDMO specialist Cerbios-Pharma SA (Cerbios) will bring its latest advances in CDMO services to the return of the landmark BIO International Convention as a physical event in California.
Cerbios, recently named as European CDMO of the Year for 2022, will exhibit as part of the Swiss Pavilion within the San Diego Convention Center.
Cerbios is a well-known presence at BIO events and has consistently attended the Bio International Convention, including its online manifestations during 2020 and 2021.
A strong team will be present on stand, led by Vitor Sousa, CDMO Business Development Manager for Cerbios-Pharma SA. Their networking campaign will be aimed expand the company’s CDMO business and client portfolio for its offerings.
Cerbios services include development and cGMP manufacturing of Antibody Drug Conjugates (ADCs), monoclonal antibodies (mAbs), Highly Potent Active Pharmaceutical Ingredients (HPAPIs), new chemical entities (NCEs) and generic Active Pharmaceutical Ingredients (APIs) production.
Cerbios further expands its services portfolio with its PROVEO™ division, a fully integrated end-to-end service for the development and manufacturing of ADCs, from mAbs and payloads to conjugation and F&F, in partnership with AGC Biologics and Oncotec Pharma Produktion. The Team in San Diego will be emphasizing the most important Cerbios advantages as one of the only CMOs worldwide that can offer, via its PROVEO™ division, a simplified documentation, full integration, complete supply chain, providing also a QbD/DoE Process Development approach for cGMP manufacturing up to commercial stage.
Cerbios is a privately held company located in Lugano, Switzerland, specialized in manufacturing Pharma Products and in offering CDMO services.
Cerbios is the ideal CDMO partner from clinical to commercial supply of API, HPAPIs, Payloads, ADCs, Proteins and Antibodies. Services offered include Process & Analytical Development, Scale-up and Clinical Supply, Industrial Validation, Commercial Supply, Full CMC Regulatory Support. Proveo (TM) is a Cerbios division recently created to provide end-to-end development and manufacturing services for ADCs.
Cerbios is also a global leading supplier of a portfolio of Generic APIs primarily used in Oncology and for the treatment of Respiratory and Dermatological disorders. Cerbios has additionally a 40 years’ experience in the probiotics field: the portfolio includes a FDF based on proprietary strain SF68® for treatment of diarrhea and dysbiosis by antibiotics and two new Food Supplements for the management of ACNE & Seborrheic dermatitis and to boost immune response.
Learn more at: https://cerbios.swiss
About BIO International 2022
Returning as a face-to-face event, the 28th BIO International Convention (BIO 2022) provides a week of intensive networking for biotechnology and pharma leaders to discover new opportunities and promising partnerships. It attracts more than 16,000 delegates involved in a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.
BIO International 2022 returns to California, as a four -day event opening June 13 at the San Diego Convention Center. The convention will feature more than 47,000 face-to-face meetings for some 7,000 companies organized using the proprietary BIO One-on-One partnering™ system, as well as hundreds of individual company presentations, a program of world-renowned keynote speakers and some 20 Session Tracks.
A co-located trade show will feature more than 1,800 exhibitors from fields ranging from digital health and diagnostics to bioprocesses.
The event is organized by the Washington DC-based Biotechnology Innovation Organization with more information at: http://convention.bio.org/
Click on Cerbios-Pharma at BIO 2022 for more information.